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Prevalence Of cOMOrbiditeS aMOng PatientS With PSOriaSiS (PSO) 
With and WithOut PSOriatic arthritiS (PSa) in eurOPean uniOn (eu)
Narayanan S.1, Franceschetti A.2
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: Assess the prevalence of comorbidities among PsO patients with PsA 
(PsO+PsA) and without PsA (PsO-alone) treated with biologics in UK/Germany/
France/Italy/Spain (5EU). MethOds: A multi-country multi-center medical chart-
review study of PsO patients was conducted in 4Q2012 among physician (mainly-
dermatologists) in hospitals and private practices to collect de-identified data on 
patients who were recently treated with a biologic as part of usual care. Physicians 
were screened for duration of practice (3-30 yrs) and patient volume (incl. > 2 PsO 
biologic patients/month) and recruited from a large panel to be geographically rep-
resentative in each country. Physicians abstracted charts of next five consecutive 
patients within each center/practice, and collected patient diagnosis/symptomatol-
ogy, disease-severity (physician-judgment), comorbidities and treatment patterns/
dynamics. Prevalence of comorbidities among PsO+PsA and PsO-alone patients 
was evaluated. Results: 1064 eligible Psoriasis patients were included in the 
analysis (UK:19%, Germany:21%, France:21%, Italy:18%, SP:22%). Prevalence of PsA 
among PsO patients was: 13% (UK:13%, Germany:16%, France:15%, Italy:9%, SP:13%), 
thereby defining PsO+PsA(13%) and PsO-alone(87%) cohort size. Patient character-
istics differed between patient groups (All/PsO+PsA/PsO-alone)- age:48/49/47yrs; 
female:38%/46%.37%; in-remission:42%/48%/41%; mild-disease-severity:23%-
each; moderate-disease-severity:23%/18%/23%; severe-disease:13%/11%/13%; UK 
(20%) and Germany (30%) had disproportionately more severe patients within 
PsO+PsA and PsO-alone groups respectively. Comorbidities (> = 1) were observed 
in 55% of patients (UK:55%, Germany:52%, France:63%, Italy:44%, SP:59%); top-10 
comorbidities observed were (All/PsO+PsA/PsO-alone): obesity(20%/27%/19%), 
dyslipidemia(19%/21%/19%), diabetes(12%/19%/11%), anxiety(8%/10%/8%), heart 
disease(7%/6%/7%), depression(6%-per-group), liver disease(4%/8%/3%), migraine/
headache(2%/4%/2%), asthma(2%/3%/2%), osteoarthritis(2%/2%/1%). Skin cancer, 
IBD, ankylosing spondylitis and other respiratory conditions were ~1% each per 
group. Key comorbidity outliers were (country:All/PsO+PsA/PsO-alone): dyslipidemia 
(Spain:28%/40%/27%), obesity (Spain:24%/43%/21%), diabetes (France:16%/21%/15%), 
anxiety (France:17%/24%/15%), heart disease (Germany:15%/14%/15%), liver-disease 
(Spain:7%/17%/5%). cOnclusiOns: Burden of comorbidities among Psoriasis 
patients is high, and significantly more so among subset of patients with PsA. This 
burden varied within 5EU. A multi-faceted approach to patient management is war-
ranted to manage these patients optimally and alleviate disease burden.
PMS4
iMPact Of aPreMilaSt On PhySical functiOn in PatientS With 
PSOriatic arthritiS
Zhang F.1, Tencer T.1, Clancy Z.2, Li S.1
1Celgene Corporation, Summit, NJ, USA, 2Celgene Corporation, Warren, NJ, USA
Objectives: The PALACE 1 study compared the efficacy and safety of apremilast 
(APR) with placebo in patients with active psoriatic arthritis despite prior conven-
tional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. The 
objective of the study was to assess the impact of APR therapy on physical func-
tioning in patients enrolled in the PALACE 1 study. MethOds: Patients were rand-
omized 1:1:1 to placebo, APR 20 mg BID (APR20), or APR 30 mg BID (APR30) stratified 
by baseline DMARD use (yes/no). Treatment efficacy was assessed at Week 16 based 
on the full analysis set population. Physical function, a pre-specified secondary 
end point, was measured in patients using the 36-item Short-Form Health Survey 
version 2 (SF-36v2) Physical Function (PF) domain, SF-36v2 physical component 
summary (PCS), and Health Assessment Questionnaire-Disability Index (HAQ-DI) 
scores. Results: 504 patients were randomized (49.4%: male; mean age: 50.4 years). 
At Week 16, the physical function change from baseline was significantly improved 
with APR30 vs. placebo, as measured by the SF-36v2 PF (4.23 vs. 1.81; P= 0.006), 
SF-36v2 PCS (4.59 vs. 2.39; P= 0.0097), and HAQ-DI (-0.244 vs. -0.086; P= 0.0017) scores. 
APR20 was associated with a significant improvement in the HAQ-DI score (-0.198 
vs. -0.086; P= 0.025), but not in the SF-36v2 PF (3.5 vs. 1.81; P= 0.050) and SF-36v2 PCS 
(3.53 vs. 2.39; P= 0.175) scores at Week 16. cOnclusiOns: While both APR30 and 
APR20 showed a benefit in disability over 16 weeks, APR30 is consistently effective 
as measured by the improvement compared with placebo in the SF-36v2 PF, SF-36v2 
PCS, and HAQ-DI scores in patients with active psoriatic arthritis.
PMS5
cOMParative efficacy Of nOvel dMardS aS MOnOtheraPy and in 
cOMbinatiOn With MethOtrexate in rheuMatOid arthritiS PatientS 
With an inadequate reSPOnSe tO traditiOnal dMardS – a netWOrk 
Meta-analySiS
Buckley F.1, Best J.H.2, Dejonckheere F.3, Finckh A.4, Huizinga T.5, Jansen J.P.6
1Mapi, Boston, MA, USA, 2Genentech, Inc., South San Francisco, CA, USA, 3F. Hoffmann-La Roche 
Ltd., Basel, Switzerland, 4University of Geneva, Geneva, Switzerland, 5Leiden University, Leiden, 
The Netherlands, 6CA, USA
Objectives: To compare ACR responses between novel DMARDs, either as mono-
therapy or in combination with methotrexate (MTX), including subcutaneous (SC) 
abatacept and SC tocilizumab (TCZ), in RA patients with an inadequate response 
to conventional DMARDs (DMARD-IR). MethOds: A systematic literature review 
identified 30 randomized clinical trials (RCTs) that evaluated abatacept (intravenous 
[IV] and SC), anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, inf-
liximab, tofacitinib, and TCZ (IV and SC). Reported treatment effects--ACR responses 
at 24 weeks--were synthesized by means of Bayesian network meta-analyses to 
compare the different treatments as monotherapy and combination therapy. The 
effects of anti-tumor necrosis factor (aTNF) therapy were assumed to be inter-
changeable. aTNF data were pooled. Results: The combination therapies aTNFs 
+ MTX, tofacitinib + MTX, abatacept IV/SC + MTX, and TCZ IV/SC + MTX dem-
onstrated comparable ACR responses while anakinra + MTX was less efficacious. 
Objectives: Evaluate treatment patterns, health care utilization and costs of 
chronic hepatitis C (CHC) patients receiving direct-acting antiviral (DAA) protease 
inhibitors. MethOds: Adult patients with ≥ 1 claim for CHC (ICD-9-CM codes 070.44, 
070.54, 070.70, 070.71) and a fill of boceprevir or telaprevir were selected from a 
de-identified US-based claims database (2006-2012). The date of the first fill for a 
DAA after 5/13/2011 (date of first DAA availability) was defined as the index date; 
patients were categorized into either the telaprevir or boceprevir cohorts. Patients 
had continuous eligibility and no claims for hepatitis B during the 6-months before 
(baseline) and 12-months following (study period) the index date. Baseline charac-
teristics and study period treatment patterns, health care utilization and costs were 
described. Adjusted study period costs were compared between the DAA cohorts 
using multivariate analyses. Results: There were 871 telaprevir and 284 boceprevir 
patients identified. DAA patients were 54 years old on average and more often male 
(62%). Approximately 25% of telaprevir and 18% of boceprevir patients had cirrhosis, 
and 9% of telaprevir and 7% of boceprevir patients had decompensated cirrhosis 
at baseline. Less than 1% of patients were HIV co-infected. Approximately 54% 
of telaprevir and 74% of boceprevir patients did not complete minimum recom-
mended therapy (telaprevir: 12 weeks of triple+12 weeks of dual, boceprevir: 4±1 
weeks of lead-in+24 weeks of triple). During the study period, over half of patients 
had anemia (boceprevir: 55%, telaprevir: 54%). Study period health care utilization 
measures were generally similar between the DAA cohorts. Telaprevir patients expe-
rienced numerically higher study period unadjusted medical (boceprevir: $16,927, 
telaprevir: $19,519) and drug costs (boceprevir: $59,953, telaprevir: $76,497) than 
boceprevir patients; however, after adjusting for baseline characteristics, only drug 
costs remained significantly different. cOnclusiOns: CHC patients receiving 
telaprevir or boceprevir experienced high rates of early discontinuation and high 
medical and drug costs.
MuScular-Skeletal diSOrderS – clinical Outcomes Studies
PMS1
a cOMParative Study On Medical care cOStS including MedicatiOn 
and injectiOn fee betWeen caSeS With/WithOut hOSPital-acquired 
fallS at a teaching hOSPital in jaPan
Egami K.1, Hirose M.2, Tsuda Y.1, Honda J.1, Shima H.1
1St. Mary’s Hospital, Kurume, Japan, 2Shimane University Hospital, Izumo, Japan
Objectives: This study aims to explore medical care costs between cases with/
without hospital-acquired falls using prospective payment system data accord-
ing to ICD10. MethOds: We had 23,336 in-patients with more than 16 years old 
between April, 2010 and March, 2012 at St. Mary’s Hospital in Kurume, Japan. There 
were 387 injured cases for falls. We examined length of hospital stay (LOS), Falls rate 
and medical care cost including medication and injection fee during hospitaliza-
tion. Results: We classified two groups, 387 injured cases with falls and 22,949 
cases without falls. The average age (mean ± standard deviation) were 72.0 ± 14.2 
years old for cases with falls and 59.7 ±20.3 y.o. for cases without falls. The LOS 
were 68.3 ±95.4 days and 18.9 ± 28.4 days. According to ICD10, LOS for Mental and 
Behavioral Disorders (F00-F99) was the longest (61.6 days) and Falls rate was the 
highest (90.9 1000pt･days). LOS for Factors influencing health status and contact 
with health services (Z00-Z99) among ICD10 codes and Falls Rate was the lowest 
(0 1000pt･days) among ICD10 codes. We assessed the highly positive association 
between length of hospital stay and Falls rate (y = 0.0016x - 0.013, R² = 0.8601). Total 
medical care cost were 26,971 USD for injured cases with falls and 9,937 USD for 
cases without falls, medication fee were 565 USD cases with falls and 162 USD for 
cases without falls, and injection fee were 2002 USD for injured cases with falls and 
670 USD for cases without falls. cOnclusiOns: We realized the length of hospital 
stay is longer, Falls rate is higher and total medical care cost, medication fee, and 
injection fee are higher. In order to prevent hospital-acquired falls, we have to 
make assessments for falls and take an appropriate measure from the viewpoint 
of ICD10 codes.
PMS2
riSk factOrS that Predict nerve injury fOllOWing SPine Surgery
Cizik A.M., Devine B., Babigumira J.B., Lee M.J.
University of Washington, Seattle, WA, USA
Objectives: A technical nerve injury is a new or worsening nerve injury follow-
ing spine surgery. These injuries can be sub-categorized into cord injuries (new or 
worsening injury of the spinal cord or cauda equina injury), and radiculopathies 
(new or worsening sensory or motor deficit that follows the distribution of a specific 
nerve root). The goal of this study was to assess the risk factors that predict technical 
nerve injury from spine surgery. MethOds: The Spine End Results Registry (SERR) 
is a prospective data registry of all patients (N= 1745) who underwent spine surgery 
from 1/1/2003 to 12/31/2004, at two academic hospitals. We modeled the predictive 
probability of various medical risk factors contributing to a technical nerve injury 
using a logistic random intercept model. The model was adjusted for diagnosis 
group, comorbidities, surgical invasiveness, age and gender, with a random inter-
cept term (surgeon), accounting for correlation, and a random slope (surgeon year 
of experience). A shrinkage estimator was used to predict the random effect of a 
surgeon. Surgical invasiveness is a score summed for the number of vertebral levels 
decompressed, arthrodesed, or instrumented, and surgical approach. Results: The 
adjusted multivariate regression analyses, the odds of a patient experiencing a tech-
nical injury was 0.008 (95% CI: 0.001, 0.042). The odds of a technical injury is < 1% for 
the average patient. No medical risk factors were significantly associated with the 
probability of experiencing a technical injury during surgery. The odds of a technical 
injury increased by 6% within a patient for each unit difference in surgical invasive-
ness (OR= 1.06, 95% CI: 1.03, 1.09, p < 0.001). cOnclusiOns: There was insufficient 
evidence from the data to suggest that medical risk factors are associated with the 
probability of a technical injury. The highest probability of experiencing a technical 
injury following spine surgery is having a more invasive surgery.
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(14≤ age≤ 75 years) with class I, IIa, or IIb MG according to Osserman’s classifica-
tion are enrolled, and are blindly separated into Chinese herb group and control 
group. The Chinese herb group is treated with Huangqi formula and control group 
with placebo, treatment duration is four weeks. Muscle weakness is assessed by 
Chinese Score for MG (CSMG; rang 12-60; higher scores worse weakness), and QoL 
is assessed by the SF-36 (rang: 0-100; higher scores better QoL); Both CSMG and 
SF-36 are evaluated at the enrollment and after four-week treatment. Results: 
Analysis is based on 248 patients (male 110, 44%; age:46±18 year), of whom 125 
patients randomized into the Chinese herb group and 121 finish the treatment; 
123 in the control group and 120 finish the study. There is no significant differ-
ence in demographic and clinical characteristics between two groups (P> 0.05), and 
no difference in CSMG (Chinese herb vs control groups: 24.1±5.9 vs 23.3±6.6) and 
SF-36 (55.7±16.6 vs 57.7±16.5) at the baseline either. After four-week treatment, 
muscle weakness declined 6.4±5.0 in Chinese herb group and 1.0±3.8 in control 
group (P= 0.000). However, no significant changes are found in SF-36 scores between 
the two groups (56.7±16.1 and 57.1±15.9). cOnclusiOns: This study proves that 
Chinese herb can relieve MG patients’ muscle weakness, but it is not enough to 
improve patients’ QoL in four weeks.
PMS9
factOrS aSSOciated With the initiatiOn Of biOlOgic diSeaSe 
MOdifying antirheuMatic drugS in texaS Medicaid PatientS With 
rheuMatOid arthritiS
Kim G., Barner J.C., Rascati K.L., Richards K.M.
The University of Texas at Austin, Austin, TX, USA
Objectives: To examine if: (1) time to initiation (TTI) of biologic DMARD therapy 
(B-DMARD) differs by non-biologic DMARD (NB-DMARD) type and therapy; and 
(2) likelihood of initiation of B-DMARD differs by NB-DMARD type and therapy 
while controlling for covariates. MethOds: Texas Medicaid medical and pre-
scription claims from 7/1/03-12/31/10 were extracted for adults (18-63 years) 
who were diagnosed with rheumatoid arthritis (ICD-9 CM 714.0x) with no use of 
DMARDs in the preindex period. The index date was the first date of NB-DMARD 
use. The likelihood of initiating B-DMARDs was compared among on NB-DMARD 
type [methotrexate(MTX), sulfasalazine(SSZ), hydroxychloroquine(HCQ), 
leflunomide(LEF)] and NB-DMARD therapy (mono vs. dual), while controlling for 
demographic factors (age, gender, race), NB-DMARD adherence [proportion of days 
covered (PDC)≥ 70% vs. < 70%], persistence, pain medication, glucocorticoid use, and 
Charlson Comorbidity Index score (CCI). Descriptive statistics, Kaplan-Meier, Log-
rank test, and logistic regression were utilized. Results: The subjects (n= 2,714) 
were 48.1±10.4 years old, primarily female (89.1%), and Hispanic (55.3%). The major-
ity were on pain medications (92.4%), glucocorticoid users (64.9%), and NB-DMARD 
monotherapy users (86.4%); while, 24.3% initiated on B-DMARDs and 46.7% had a 
CCI score= 1. Compared to TTI (days) of B-DMARDs for MTX (208.3±190.1) users, TTI of 
B-DMARDs was longer for SSZ (284.5±186.4) and HCQ (256±184.4) users and shorter 
for LEF users (188.0±205.1);p< 0.0001). There were no differences between mono 
and dual therapy users. After controlling for covariates, regression results showed 
that compared to MTX, SSZ users were 66.8% less likely (OR= 0.322;95%CI= 0.237-
0.464;p< 0.0001) and HCQ users were 79.0% less likely (OR= 0.210;95%CI= 0.160-
0.278;p< 0.0001) to initiate B-DMARD therapy. NB-DMARD monotherapy users were 
47.5% more likely (OR= 1.475;95%CI= 1.121-1.940;p< 0.0001) to initiate B-DMARD 
therapy compared to dual therapy users. cOnclusiOns: Time to B-DMARD ini-
tiation ranged from 6.3 (LEF) to 9.5 months (SSZ). Patients who used NB-DMARD 
MTX and those on monotherapy may be more likely to initiate on B-DMARD therapy.
PMS10
cOMParing MethOdS Of biaS adjuStMent fOr Meta-analySiS 
Of ObServatiOnal data tO evaluate vertebral augMentatiOn 
PrOcedureS fOr treating OSteOPOrOtic vertebral cOMPreSSiOn 
fractureS
Dequen P., Cooper N.J., Abrams K.R.
University of Leicester, Leicester, UK
In April 2013, percutaneous vertebroplasty (PVP) and balloon kyphoplasty (BKP) 
without stenting—two vertebral augmentation procedures—were recommended 
by NICE to treat vertebral compression fractures (VCFs) due to osteoporosis (TA279). 
Although all-cause mortality was assessed as a secondary outcome, evidence from 
included RCTs did not achieve statistical significance, even when pooled, comparing 
operated patients (PVP or BKP) to patients receiving only optimal pain management 
(OPM). The Evidence Review Group stated that the effect of vertebral augmentation 
on mortality was an important, yet inadequately understood issue, despite evi-
dence of improved survival from recently published large-scale registry studies from 
Germany and the United States. Objectives: To estimate the mortality differences 
between treatments for osteoporotic VCFs by pooling randomised and observa-
tional data using Cox regression, propensity score matching, as well as, Thompson 
et al.’s (2010) and Welton et al.’s (2009) bias adjustment methods. MethOds: We 
extended the random effects meta-analysis from NICE’s TA279 to include observa-
tional data extracted from German and US (Medicare) insurance claims databases 
to estimate the mortality effect of PVP versus OPM and BKP versus OPM. All adjust-
ment methods were compared and evaluated using a simple cost-effectiveness 
model. PReliMinARy Results: Survival hazard ratios were statistically significant, 
using all methods, in favour of either vertebral augmentation procedures versus 
OPM. The uncertainty in resulting estimates was artificially inflated to assess the 
level of uncertainty required to reach < 50% probability of cost-effectiveness at 
common threshold values. Mortality benefit was shown to be a key driver of cost-
effectiveness, particularly for BKP. cOnclusiOns: Cox regression and propensity 
scoring adjustments are reliant on covariate information and thus may not capture 
all sources of bias; other proposed adjustment methods may play a pivotal role in 
assessing real-word evidence. An application of these methods to network meta-
analysis is currently being undertaken to simultaneously compare operated patients 
with patients receiving OPM.
Among biologic monotherapies, greater ACR20/50/70 responses were observed with 
TCZ IV than with aTNFs and tofacitinib. When comparing biologics + MTX with 
biologic monotherapies, ACR20, ACR50, and ACR70 responses with TCZ + MTX were 
similar to TCZ as monotherapy (OR= 1.04, 95% CI, 0.39-2.80; OR= 1.28, 95% CI, 0.46-
3.51; OR= 0.97, 95% CI, 0.38-2.49, respectively). Greater ACR20/50/70 responses were 
observed with aTNF + MTX than with aTNF monotherapy (OR= 2.22; 95% CI, 0.46-
10.83, probability better= 84%; OR= 3.12, 95% CI, 0.60-16.32, probability better= 92%; 
OR= 1.39, 95% CI, 0.26-6.78, probability better= 68%, respectively). Sensitivity analyses 
showed conflicting results for the indirect comparison of tofacitinib + MTX versus 
tofacitinib. cOnclusiOns: Results suggest that most of the novel DMARDs, in 
combination with MTX, have similar levels of efficacy in DMARD-IR patients. As 
monotherapy, TCZ is likely to have a greater response than aTNFs and tofacitinib. 
TCZ monotherapy also shows comparable efficacy compared to TCZ + MTX, whereas 
aTNFs in combination with MTX showed greater ACR responses compared with 
aTNF monotherapy at 24 weeks.
PMS6
Meta-analySiS Of efficacy Of etanercePt fOr PSOriatic arthritiS
Aggarwal S., Topaloglu H., Segal J.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Psoriatic arthritis (PA) is an inflammatory disease affecting joints and 
connective tissues. The anti-tumor necrosis factor (TNF) biologics are increasingly 
being used in patients who have failed traditional disease-modifying antirheumatic 
drugs. Etanercept has shown efficacy in treatment of PA. The objective of this study 
was to conduct meta-analysis and present total evidence for etanercept in treatment 
of PA. MethOds: For this meta-analysis we included randomized controlled trials 
(RCTs)evaluating etanercept for the treatment of PS. RCTs studying adult popu-
lations with active and progressive PA with an inadequate response to previous 
DMARD therapy were eligible. Trials conducted among PA populations with prior 
experience with anti-TNF agents, including an inadequate response, were excluded. 
A systematic literature search for Etanercept trials was undertaken for the databases 
Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the 
study size, interventions, year, and the three outcomes HAQ, PASI and PsARC. For 
meta-analysis, random effects and fixed effects models were used to obtain cumula-
tive statistics. Results: Two RCTs with a total of 131 patients were identified. The 
pooled response rates for Etanercept for PsARC were 75% (95% CI 60%-90%), for HAQ 
were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 13%-34%). The pooled 
response rates for placebo for PsARC were 30% (95% CI 26%-35%), for HAQ were 5% 
(95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). For PsARC the cumulative 
relative risk with Etanercept versus placebo was 0.40 (95% CI 33%-48%). For HAQ, the 
cumulative relative risk with placebo versus Etanercept was 0.08 (95% CI 5%-12%). 
For PASI, the cumulative relative risk with placebo versus Etanercept was 0.14 (95% 
CI 8%-20%). cOnclusiOns: Meta-analysis shows Etanercept offers patients with 
psoriatic arthritis an effective therapeutic option for control of their disease.
PMS7
real-WOrld utilizatiOn Of certOlizuMab PegOl (czP) fOr the 
treatMent Of rheuMatOid arthritiS (ra) in the united kingdOM
Bedenbaugh A.V.1, Qizilbash N.2, Dunkel J.3, SanJose B.4, Méndez I.4
1UCB Pharma, Smyrna, GA, USA, 2OXON Epidemiology Limited and Department of Primary Care 
and Public Health, Imperial College, London, UK, 3UCB Pharma, Monheim, Germany, 4OXON 
Epidemiology Limited, Madrid, Spain
Objectives: Certolizumab pegol (CZP) is an anti-TNF approved for rheumatoid 
arthritis (RA) in the UK. Based on 12 week clinical data, NICE guidance recommends 
CZP as first-line biologic therapy for RA treatment, in conjunction with a Patient 
Access Scheme (PAS) providing the initial 12 weeks of CZP free of charge to UK NHS. 
The objective was to assess real-world CZP utilization. MethOds: A retrospec-
tive, observational cohort analysis was conducted in four UK Rheumatology clinics. 
Chart data was collected for biologic-naïve RA patients initiating CZP, followed up 
to 52 weeks. Reported data included: baseline characteristics, persistence at Weeks 
12/24/52, concomitant medication and PAS cost impact. Results: 110 CZP patients 
were analysed. Baseline characteristics: mean age 57.4 years, 65.5% female, mean 
DAS 6.1. Data was collected for 110, 108 and 82 patients over 12, 24 and 52 weeks, 
respectively (a certain number of patients’ data was only available for portions 
of the 52-week retrospective follow-up). At baseline, 68.2% patients received con-
comitant methotrexate, 28.2% oral corticosteroids, and 14.5% CZP monotherapy. 
Kaplan-Meier persistency estimates were: 95.5%, 82.6% and 71.8% at 12, 24, 52 weeks, 
respectively. Assuming full compliance with labeled dosing, CZP cost for 52 weeks 
therapy was £10,368 per patient in England/Wales and £6,793 with the 12 weeks for 
free PAS applied. This is £2,502 and £2,363 less than comparable annual per-patient 
costs for etanercept and adalimumab, respectively. cOnclusiOns: CZP persistency 
appeared consistent with data observed in other observational studies of subcu-
taneous anti-TNFs. Application of the PAS resulted in a substantial reduction in 
1-year costs for CZP therapy in comparison to alternatives. PAS-related savings, 
adjusted for real-world persistency, will also help provide Payers with data to make 
informed decisions for options to treat RA. Interpretation of data is limited due to 
retrospective analysis caveats.
PMS8
iS chineSe herb effective On treating MyaSthenia graviS PatientS?
Zhang H.Y., Xie W.F., Zhang J.S., Yang G.L.
Liaoning University of Traditional Chinese Medicine, Shenyang, China
Objectives: Myasthenia Gravis (MG) is an auto immune disease of neuromuscular 
junction, which leads to muscle weakness and influences patients’ quality of life 
(QoL). Treatments for MG patients include thymectomy, acetylcholinesterase inhibi-
tors and immunosuppressant drugs. But in China, Chinese herb is widely used. This 
study is to prove Chinese herb’s efficacy on treating MG patients. MethOds: The 
data is performed on a random double blind clinical trial. Consecutive MG patients 
are enrolled in three hospitals in China, from July, 2008 to June, 2010. Patients 
